Login / Signup

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.

Judith TrotmanChristian BuskeAlessandra TedeschiJeffrey V MatousDavid MacDonaldConstantine S TamOlivier TournilhacShuo MaSteven P TreonAlbert OriolJerry PingEva M BrisoIsrael Arango-HisijaraMeletios A Dimopoulos
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.
Keyphrases
  • phase iii
  • chronic lymphocytic leukemia
  • open label
  • clinical trial
  • phase ii
  • diffuse large b cell lymphoma
  • double blind
  • placebo controlled
  • hodgkin lymphoma
  • study protocol
  • randomized controlled trial